PLUS1
Period:
Draw Mode:
| Volume | 57,186 |
|
|||||
| News | - | ||||||
| Day High | 70.81 | Low High |
|||||
| Day Low | 70.51 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Incyte Corporation | INCY | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.34 | 0.48% | 70.65 | 09:55:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 70.73 | 70.51 | 70.81 | 70.31 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,196 | 57,186 | $ 70.63 | $ 4,039,158 | - | 65.07 - 86.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:56:02 | 1 | $ 70.69 | USD |
Incyte Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 15.75B | 222.97M | 184.07M | $ 3.39B | $ 340.14M | 1.51 | 46.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 185.41k | 1.60% |
Incyte News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INCY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 73.52 | 73.855 | 67.83 | 71.07 | 1,883,446 | -2.87 | -3.9% |
| 1 Month | 77.01 | 78.02 | 67.83 | 73.67 | 1,516,092 | -6.36 | -8.26% |
| 3 Months | 80.13 | 86.29 | 67.83 | 78.63 | 1,705,911 | -9.48 | -11.83% |
| 6 Months | 67.42 | 86.29 | 66.135 | 77.48 | 1,540,094 | 3.23 | 4.79% |
| 1 Year | 78.91 | 86.29 | 65.07 | 76.47 | 1,476,276 | -8.26 | -10.47% |
| 3 Years | 70.20 | 111.05 | 61.91 | 79.96 | 1,473,116 | 0.45 | 0.64% |
| 5 Years | 85.06 | 111.05 | 57.00 | 77.46 | 1,509,560 | -14.41 | -16.94% |
Incyte Description
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |